The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
so that's a thyroid hormone receptor um Agonist uh that has been studied and now shows very good promise in terms of um late stage efficacy — late stage by way of phase three — efficacy and safety in a population you know a couple couple of um limitations in terms of the population I think it's 90% European ancestry or self-described white
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.